Greenwich Lifesciences Inc
NASDAQ:GLSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Greenwich Lifesciences Inc
NASDAQ:GLSI
|
US |
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
CN |
|
Ichia Technologies Inc
TWSE:2402
|
TW |
|
Rarex Ltd
ASX:REE
|
AU |
|
S
|
Sweet Poison Spirits Inc
CNSX:SPS
|
CA |
|
Medicenna Therapeutics Corp
TSX:MDNA
|
CA |
|
A
|
Allianz Malaysia Bhd
KLSE:ALLIANZ
|
MY |
|
B
|
Bambuser AB
STO:BUSER
|
SE |
|
Academy Sports and Outdoors Inc
NASDAQ:ASO
|
US |
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
US |
|
Independent Bank Corp (Michigan)
NASDAQ:IBCP
|
US |
|
Arcticzymes Technologies ASA
OSE:AZT
|
NO |
|
National Health Investors Inc
NYSE:NHI
|
US |
|
Indra Sistemas SA
F:IDA
|
ES |
|
Sayona Mining Ltd
ASX:SYA
|
AU |
Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is developing, GP2, a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is developing, GP2, a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.
